At Integrated Health Clinic (IHC), we have continuously searched the world over, for the most advanced testing available in the fight against cancer.

What follows is just a smattering of the many cool and exciting tests we offer to our patients at IHC. These are tests not commonly available through the usual healthcare system:

1. Select MDx (LifeLabs):
   • Select MDx is a urine test that measures two cancer-related genetic biomarkers, HOXC6 and DLX1. Combined with other clinical factors like total PSA and age, the test produces a likelihood score of discovering clinically significant disease (defined as Gleason Score equal to or more than 7 [3+4 and 4+3]).
   • This provides you and your doctor with another important piece of information to consider when recommending whether a biopsy is required and potentially avoid unnecessary procedures.
   • The test has a very high negative predictive value, meaning that a low likelihood result is correct in the vast majority of men (Negative Predictive Value (NPV) of 98% for clinically significant cancer).
2. DermTech (USA):
   • The DermTech Melanoma Test is a non-invasive genomic test utilizing DermTech Smart Stickers™ to assess suspicious melanocytic lesions meeting one or more of the ABCDE criteria.
   • It detects genomic markers associated with melanoma to identify high-risk lesions at their earliest stages.
   • The test provides objective, actionable, easy-to-interpret results that distinguish benign from high-risk lesions, with >99% probability of determining that a lesion is not melanoma. Informing next steps.
   • Indicated for use on melanocytic lesions having one or more ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolving)
     • Additional considerations for use may include⁵:
     • Difficult-to-biopsy areas
     • Cosmetically sensitive areas
     • Patients who are not good biopsy candidates

3. Color Genetic Testing (USA):
   • Provides patients, clinicians, and researchers with genetic information to guide optimal health care.
   • Know what your genes say about your risk for common cancers and heart conditions — and how your body might process certain medications.
   • Accessible, clinical-grade genetic testing, including all 10 genes recognized by the CDC as important for public health.
   • An affordable clinical-grade test that historically has cost thousands of dollars.
   • Includes phone calls with a genetic counselor to get answers.
4. Maintrac CTC (Germany):
   • maintrac^®allows a direct assessment of tumor activity, by measuring circulating tumor cells (CTCs) and the chance to check the effectiveness of the therapy being used.
   • It allows relapses to be detected early and in an ideal scenario, therapeutic approaches can be adapted in good time.
   • Generally, maintrac^®can be used for all tumors of epithelial origin (=carcinomas), particularly breast, colorectal, lung and prostate cancers, with most clinical studies carried out involving breast cancer.
5. Guardant 360 (USA):
   • Guardant360^®CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors, requiring only a blood test.
   • Indicated for stage 3 and 4 patients who do not already have molecular testing data, are unable to get or want to avoid a biopsy, and in those in whom tissue testing was incomplete at initial diagnosis.
   • Benefit from this cell-free DNA genotyping to access truly personalized therapy for cancer, includes TMB, MSI status, and PD-L1, if ordered.
   • Get the complete picture before choosing treatment.
   • Test turnaround time of only 2-3 weeks from blood sample to results.
6. Cologuard (USA):
   • This stool test has been included in the US Preventative Services Task Force guidelines as an A-rated screening tool. Not to be uses as a replacement for colonscopy in those over 45 years of age.
   • It is a multi-target stool DNA test that looks for KRas mutations, aberrant NDRG4/BMP3 methylation, Beta-actin, and Hb immunoassay.
   • It has a better sensitivity for colorectal cancer (92.3%) and for precancerous lesions or polyps (42.4%) than the standard FIT test, but a poorer sensitivity than FIT (86.6%). This means it is better at detecting cancer, but can have more false positives.
   • As with all tests, Cologard results need to be interpreted wisely, and alongside a careful history, physical examination, appropriate scope(s), FIT testing, and other appropriate medical observation.

If you want to know what novel cutting edge cancer testing options are available for you at IHC, please give the clinic a call: 604-888-8325.